Neha Krishnamohan - 01 Dec 2022 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Chief Financial Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Dec 2022
Net transactions value
-$11,307
Form type
4
Filing time
02 Dec 2022, 19:00:15 UTC
Previous filing
06 Sep 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability $11,307 -1,459 -2.1% $7.75 69,099 01 Dec 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,543 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022.
F2 Includes 63,282 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.